cyclosporine ophthalmic
Selected indexed studies
- Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. (Ophthalmology, 2000) [PMID:10768324]
- Exploring the Therapeutic Potential of Cyclosporine for Ophthalmic Indications by Novel Carrier Systems. (Crit Rev Ther Drug Carrier Syst, 2023) [PMID:37522548]
- Unusual Photophobia in a Child. (JAMA Ophthalmol, 2016) [PMID:27490065]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. (2000) pubmed
- Exploring the Therapeutic Potential of Cyclosporine for Ophthalmic Indications by Novel Carrier Systems. (2023) pubmed
- Unusual Photophobia in a Child. (2016) pubmed
- Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease. (2019) pubmed
- The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options. (2020) pubmed
- Cyclosporine A Nanosuspensions for Ophthalmic Delivery: A Comparative Study between Cationic Nanoparticles and Drug-Core Mucus Penetrating Nanoparticles. (2021) pubmed
- Solubilization of Cyclosporine in Topical Ophthalmic Formulations: Preformulation Risk Assessment on a New Solid Form. (2019) pubmed
- Ophthalmic cyclosporine in equine keratitis and keratouveitis: 11 cases. (1995) pubmed
- Use of cyclosporine A 0.05% ophthalmic emulsion for a distinctive intrapalpebral phenotype of anterior scleritis. (2025) pubmed
- Comparative study of cyclosporine A liposomes and emulsions for ophthalmic drug delivery: Process optimization through response surface methodology (RSM) and biocompatibility evaluation. (2023) pubmed